Anti-inflammatory effects of Resveratrol, Curcumin and Simvastatin in acute small intestinal inflammation

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Bereswill, Stefan ^a   Muñoz, Melba ^a   Fischer, André ^a   Plickert, Rita ^a   Haag, Lea Maxie ^a   Otto, Bettina ^a   Kühl, Anja A ^a   Loddenkemper, Christoph ^a   Göbel, Ulf B ^a   Heimesaat, Markus M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 23P19; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; RESVERATROL; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL TRANSLOCATION; BACTERIUM DETECTION; BIFIDOBACTERIUM; BLOOD; CELL PROLIFERATION; CELL REGENERATION; CONTROLLED STUDY; DOWN REGULATION; ENTEROBACTERIACEAE; ENTEROCOCCUS; EPITHELIUM CELL; ILEITIS; ILEUM MUCOSA; IMMUNOMODULATION; INTESTINE FUNCTION; KIDNEY; LACTOBACILLUS; LIVER; MESENTERY LYMPH NODE; MOUSE; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY T LYMPHOCYTE; SPLEEN; SURVIVAL RATE; TH1 CELL; TOXOPLASMA GONDII; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; INFLAMMATION; METABOLISM; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; SMALL INTESTINE; TOXOPLASMA;

ANIMALIA; BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; MURINAE; MUS; TOXOPLASMA GONDII;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CURCUMIN; DISEASE MODELS, ANIMAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ILEITIS; INFLAMMATION; INTESTINE, SMALL; MICE; MICE, INBRED C57BL; SIMVASTATIN; STILBENES; TH1 CELLS; TOXOPLASMA;

EID: 78649918795     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015099     Document Type: Article

References (40)

1. Jain SK (1994) Ethnobotany and research on medicinal plants in India. Ciba Found Symp 185: 153-164; discussion 164-158.
2. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, et al. (1995) Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333: 621-627.
3. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342.
4. Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B (2007) Effects of resveratrol in inflammatory arthritis. Inflammation 30: 1-6.
5. Ma ZH, Ma QY, Wang LC, Sha HC, Wu SL, et al. (2005) Effect of resveratrol on peritoneal macrophages in rats with severe acute pancreatitis. Inflamm Res 54: 522-527.
6. Larrosa M, Yanez-Gascon MJ, Selma MV, Gonzalez-Sarrias A, Toti S, et al. (2009) Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J Agric Food Chem 57: 2211-2220.
7. Calabrese V, Butterfield DA, Stella AM (2003) Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: novel targets for neuroprotection in Alzheimer's disease. Ital J Biochem 52: 177-181.
8. Huang TS, Lee SC, Lin JK (1991) Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci U S A 88: 5292-5296.
9. Sugimoto K, Hanai H, Tozawa K, Aoshi T, Uchijima M, et al. (2002) Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 123: 1912-1922.
10. Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, et al. (2002) Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J 23: 207-215.
11. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, et al. (2001) In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 21: 1327-1332.
12. Munoz M, Heimesaat MM, Danker K, Struck D, Lohmann U, et al. (2009) Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17. J Exp Med 206: 3047-3059.
13. Liesenfeld O, Kosek J, Remington JS, Suzuki Y (1996) Association of CD4+ T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii. J Exp Med 184: 597-607.
14. Heimesaat MM, Bereswill S, Fischer A, Fuchs D, Struck D, et al. (2006) Gramnegative bacteria aggravate murine small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii. J Immunol 177: 8785-8795.
15. Heimesaat MM, Fischer A, Jahn HK, Niebergall J, Freudenberg M, et al. (2007) Exacerbation of murine ileitis by Toll-like receptor 4 mediated sensing of lipopolysaccharide from commensal Escherichia coli. Gut 56: 941-948.
16. Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, et al. (2005) Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 128: 1868-1878.
17. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, et al. (1991) Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138: 867-873.
18. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347: 417-429.
19. Basset C, Holton J (2002) Inflammatory bowel disease: is the intestine a Trojan horse? Sci Prog 85: 33-56.
20. Liesenfeld O (2002) Oral infection of C57BL/6 mice with Toxoplasma gondii: a new model of inflammatory bowel disease? J Infect Dis 185 Suppl 1: S96-101.
21. Vossenkamper A, Struck D, Alvarado-Esquivel C, Went T, Takeda K, et al. (2004) Both IL-12 and IL-18 contribute to small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii, but IL-12 is dominant over IL-18 in parasite control. Eur J Immunol 34: 3197-3207.
22. Maher BM, Dhonnchu TN, Burke JP, Soo A, Wood AE, et al. (2009) Statins alter neutrophil migration by modulating cellular Rho activity-a potential mechanism for statins-mediated pleotropic effects? J Leukoc Biol 85: 186-193.
23. Jahovic N, Gedik N, Ercan F, Sirvanci S, Yuksel M, et al. (2006) Effects of statins on experimental colitis in normocholesterolemic rats. Scand J Gastroenterol 41: 954-962.
24. Camacho-Barquero L, Villegas I, Sanchez-Calvo JM, Talero E, Sanchez-Fidalgo S, et al. (2007) Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 7: 333-342.
25. Ung VY, Foshaug RR, MacFarlane SM, Churchill TA, Doyle JS, et al. Oral administration of curcumin emulsified in carboxymethyl cellulose has a potent anti-inflammatory effect in the IL-10 gene-deficient mouse model of IBD. Dig Dis Sci 55: 1272-1277.
26. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, et al. (1999) Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 163: 3474-3483.
27. Jian YT, Mai GF, Wang JD, Zhang YL, Luo RC, et al. (2005) Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 11: 1747-1752.
28. Martin AR, Villegas I, La Casa C, de la Lastra CA (2004) Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol 67: 1399-1410.
29. Sanchez-Fidalgo S, Cardeno A, Villegas I, Talero E, de la Lastra CA () Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur J Pharmacol 633: 78-84.
30. Fooks LJ, Gibson GR (2002) Probiotics as modulators of the gut flora. Br J Nutr 88 Suppl 1: S39-49.
31. Candela M, Perna F, Carnevali P, Vitali B, Ciati R, et al. (2008) Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol 125: 286-292.
32. Lubbad A, Oriowo MA, Khan I (2009) Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol Cell Biochem 322: 127-135.
33. Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, et al. (1999) Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 117: 814-822.
34. Claramunt RM, Bouissane L, Cabildo MP, Cornago MP, Elguero J, et al. (2009) Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases. Bioorg Med Chem 17: 1290-1296.
35. Medina C, Santana A, Paz MC, Diaz-Gonzalez F, Farre E, et al. (2006) Matrix metalloproteinase-9 modulates intestinal injury in rats with transmural colitis. J Leukoc Biol 79: 954-962.
36. Aggarwal BB, Sung B (2009) Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 30: 85-94.
37. Rapin JR, Wiernsperger N (2010) Possible links between intestinal permeablity and food processing: A potential therapeutic niche for glutamine. Clinics (Sao Paulo) 65: 635-643.
38. Ahn J, Lee H, Kim S, Ha T (2007) Resveratrol inhibits TNF-alpha-induced changes of adipokines in 3T3-L1 adipocytes. Biochem Biophys Res Commun 364: 972-977.
39. Heimesaat MM, Fischer A, Siegmund B, Kupz A, Niebergall J, et al. (2007) Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4. PLoS One 2: e662.
40. Kouri TT, Gant VA, Fogazzi GB, Hofmann W, Hallander HO, et al. (2000) Towards European urinalysis guidelines. Introduction of a project under European Confederation of Laboratory Medicine. Clin Chim Acta 297: 305-311.